权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

转移性前列腺癌中 DNA 修复的改变：功能和治疗意义

基本信息

批准号：
9901331
负责人：
Alan Ashworth
金额：
$ 5.53万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-01 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9901331
关键词：
ATM gene Affect Androgen Receptor Antiandrogen Therapy Area BRCA1 gene BRCA2 gene Bioinformatics Biological Breast Adenocarcinoma CRISPR interference Cancer Patient Cell Line Cells Clinical Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats DNA DNA Damage DNA Repair DNA Repair Gene FDA approved Future Genes Genetic Genetic Predisposition to Disease Genomic approach Genomics Human In Vitro Individual Investigation Malignant Neoplasms Mediator of activation protein Metastatic Prostate Cancer Missense Mutation Modeling Molecular Mutation Nonsense Mutation Ovarian Adenocarcinoma Pancreatic Adenocarcinoma Pathway interactions Patient Selection Patients Physicians Poly(ADP-ribose) Polymerases Pre-Clinical Model Prevalence Prostate Cancer therapy Receptor Signaling Research Design Research Personnel Resistance Sampling Scientist Selection Criteria Specimen Tertiary Protein Structure Therapeutic Tumor Biology base castration resistant prostate cancer clinical development clinically relevant cohort experience functional genomics gain of function homologous recombination improved in vivo in vivo Model inhibitor/antagonist insight novel novel therapeutics personalized cancer therapy personalized medicine predicting response prostate cancer cell repaired response targeted agent therapy resistant treatment response tumor tumor DNA

项目摘要

PROJECT SUMMARY / ABSTRACT: Metastatic castration-resistant prostate cancer (mCRPC) is, at present, almost invariably fatal. There is an urgent need to tailor mCRPC therapy to vulnerabilities present within individual tumors. Crosstalk between DNA damage response and androgen receptor (AR) signaling represents one of the most promising opportunities for personalizing prostate cancer therapy. In this application, we will investigate the mechanistic and therapeutic implications of alterations in the three most commonly altered DNA repair genes in mCRPC: BRCA2, BRCA1, and ATM. Using novel in vitro and in vivo models of homologous recombination (HR) deficiency, we will interrogate the impact of BRCA2 vs. BRCA1 vs. ATM alterations, two copy vs. one copy aberrations, and truncating vs. non-truncating mutations on homologous recombination, androgen receptor (AR) signaling, and response to PARP inhibitors or AR- directed therapies. We will then validate these findings in unique cohorts of mCRPC patients treated with these agents. Finally, we will use CRISPR-based functional genomic approaches to identify novel genetic vulnerabilities in mCPRC models that can inform the next generation of therapeutic strategies and guide the development of clinical trials. Our study will significantly advance the mCRPC field by: 1) developing the first human preclinical models of HR deficiency, 2) functionally characterizing the most prevalent BRCA2, BRCA1, and ATM alterations in mCRPC, 3) better defining the mechanistic pathways that define the response of mCRPC to PARPi and AR-directed therapies, and 4) discovering novel targets that influence these responses. Given the prevalence of BRCA2, BRCA1, and ATM alterations in other cancers, including breast, ovarian, and pancreatic adenocarcinomas, the mechanisms uncovered by these studies will have clinical implications far beyond the mCRPC space, and will represent an advance towards individualizing cancer therapy based on tumor genetic alterations.

项目总结/摘要：目前，转移性去势抵抗性前列腺癌（mCRPC）几乎总是致命的。有迫切需要针对个体肿瘤中存在的弱点定制mCRPC治疗。串扰 DNA损伤反应和雄激素受体（AR）信号之间的联系代表了个性化前列腺癌治疗的前景。在本申请中，我们将调查三种最常见的DNA改变的机制和治疗意义 mCRPC中的修复基因：BRCA 2、BRCA 1和ATM。使用新型体外和体内模型同源重组（HR）缺陷，我们将询问BRCA 2与BRCA 1与 ATM改变，两个拷贝与一个拷贝畸变，以及截短与非截短突变，同源重组、雄激素受体（AR）信号传导和对PARP抑制剂或AR- 定向治疗。然后，我们将在接受治疗的mCRPC患者的独特队列中验证这些结果与这些代理人。最后，我们将使用基于CRISPR的功能基因组方法来鉴定新的 mCPRC模型中的遗传脆弱性可以为下一代治疗策略提供信息并指导临床试验的开展。我们的研究将通过以下方式显著推进mCRPC领域：1）开发第一个HR缺陷的人类临床前模型，2）功能性表征最 mCRPC中普遍存在的BRCA 2、BRCA 1和ATM改变，3）更好地定义定义mCRPC对PARPi和AR导向疗法反应的途径，以及4）发现影响这些反应的新靶点。考虑到BRCA 2、BRCA 1和ATM的流行程度，在其他癌症，包括乳腺癌、卵巢癌和胰腺癌中，这些研究揭示的机制将具有远远超出mCRPC领域的临床意义，并将代表基于肿瘤遗传学的个体化癌症治疗的进步改变。